Search - tctmd.com

Displaying 241 - 260 of 1328

Sort: Relevancy | Date

More DAPT Duration Data, More Calls to Tailor to Individual Patients

News Conference News TCT 2021

More DAPT Duration Data, More Calls to Tailor to Individual Patients

November 05, 2021

PRAGUE-17: LAA Occlusion Noninferior to DOACs Over Longer Term

News Conference News TCT 2021

PRAGUE-17: LAA Occlusion Noninferior to DOACs Over Longer Term

November 05, 2021

OCT Guidance Cuts Stent Use in STEMI Without Plaque Rupture: EROSION III

News Conference News TCT 2021

OCT Guidance Cuts Stent Use in STEMI Without Plaque Rupture: EROSION III

November 04, 2021

‘Sweet Like SUGAR’: Polymer-Free Stent Noninferior to ZES in Diabetic Patients

News Conference News TCT 2021

‘Sweet Like SUGAR’: Polymer-Free Stent Noninferior to ZES in Diabetic Patients

Yael L. Maxwell

November 04, 2021

FAVOR III China Adds Strength to Value of QFR-Guided PCI

News Conference News TCT 2021

FAVOR III China Adds Strength to Value of QFR-Guided PCI

November 04, 2021

De-escalating Prasugrel Reduces Net Events in Complex PCI for ACS

News Conference News TCT 2021

De-escalating Prasugrel Reduces Net Events in Complex PCI for ACS

Yael L. Maxwell

October 22, 2021

Half-Dose DOAC May Be a Good Post-Watchman Option

News Daily News

Half-Dose DOAC May Be a Good Post-Watchman Option

October 14, 2021

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

News Features

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

October 08, 2021

October 2021 News Roundup

News Opinion CV Team Dispatch

October 2021 News Roundup

October 01, 2021

Title (ideally under 60 characters) DCB Match DES for Treating Coronary In-Stent Restenosis: European Registry

News Daily News

DCB Match DES for Treating Coronary In-Stent Restenosis: European Registry

September 15, 2021

Lidocaine Less Likely Than Fentanyl to Blunt P2Y12 Inhibitors in the Cath Lab

News Daily News

Lidocaine Less Likely Than Fentanyl to Blunt P2Y12 Inhibitors in the Cath Lab

September 07, 2021

OAC Analysis From MASTER DAPT Raises No Red Flags for Shorter DAPT

News Conference News ESC 2021

OAC Analysis From MASTER DAPT Raises No Red Flags for Shorter DAPT

September 02, 2021

One-month Dual Antiplatelet Therapy Followed by Clopidogrel Monotherapy in Acute Coronary Syndrome:

Presentation ESC 2021

One-month Dual Antiplatelet Therapy Followed by Clopidogrel Monotherapy in Acute Coronary Syndrome:

Presenter: Hirotoshi Watanabe

August 31, 2021

In ACS, Clopidogrel Monotherapy After 1-Month DAPT Falls Short: STOPDAPT-2 ACS

News Conference News

In ACS, Clopidogrel Monotherapy After 1-Month DAPT Falls Short: STOPDAPT-2 ACS

August 30, 2021

Amulet IDE: LAA Occluder Performs Well Against Watchman

News Conference News ESC 2021

Amulet IDE: LAA Occluder Performs Well Against Watchman

August 30, 2021

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

News Conference News ESC 2021

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

August 28, 2021

Prasugrel Tops Ticagrelor in ACS Across the eGFR Spectrum: ISAR-REACT 5

News Conference News ESC 2021

Prasugrel Tops Ticagrelor in ACS Across the eGFR Spectrum: ISAR-REACT 5

August 24, 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

News Opinion Editor's Corner ESC 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

August 19, 2021

Early Recurrent Events After Acute MI: Clues to Origins Hint at Solutions

News Daily News

Early Recurrent Events After Acute MI: Clues to Origins Hint at Solutions

August 10, 2021

Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t

News Daily News

Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t

August 04, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.